Arbutus Biopharma Corp Stock-Based Compensation
Arbutus Biopharma Corp (ABUS) reported Stock-Based Compensation of $2.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
CAD
| Period end | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|
| 2012-12-31 | 981.66K CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 626.12K CAD 20-F · filed 2013-03-27 |
| 2010-12-31 | 650.62K CAD 20-F · filed 2013-03-27 |
| 2009-12-31 | 265.69K CAD 20-F · filed 2012-03-27 |
USD
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.98M 10-Q · filed 2026-08-12 | $4.25M derived: sum of 3 quarters · filed 2026-08-12 | $5.51M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.36M 10-Q · filed 2026-05-13 | $2.62M derived: sum of 2 quarters · filed 2026-05-13 | $3.88M derived: sum of 3 quarters · filed 2026-05-13 | $4.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $2.52M derived: sum of 2 quarters · filed 2026-03-23 | $3.39M derived: sum of 3 quarters · filed 2026-08-12 | $6.95M 10-K · filed 2026-03-23 |
| 2025-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.13M derived: sum of 2 quarters · filed 2026-08-12 | $5.69M 10-Q · filed 2025-11-13 | $7.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $864.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $4.43M 10-Q · filed 2026-08-12 | $6.06M derived: sum of 3 quarters · filed 2026-08-12 | $8.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.56M 10-Q · filed 2026-05-13 | $5.20M derived: sum of 2 quarters · filed 2026-05-13 | $7.36M derived: sum of 3 quarters · filed 2026-05-13 | $10.54M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.79M derived: sum of 2 quarters · filed 2026-03-23 | $6.97M derived: sum of 3 quarters · filed 2026-03-23 | $8.99M 10-K · filed 2026-03-23 |
| 2024-09-30 | $2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.34M derived: sum of 2 quarters · filed 2025-11-13 | $7.35M 10-Q · filed 2025-11-13 | $9.08M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.19M 10-Q · filed 2025-08-06 | $6.92M derived: sum of 3 quarters · filed 2025-08-06 | $9.40M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $2.01M 10-Q · filed 2025-05-14 | $3.74M derived: sum of 2 quarters · filed 2025-05-14 | $6.22M derived: sum of 3 quarters · filed 2025-05-14 | $9.18M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $4.21M derived: sum of 2 quarters · filed 2025-03-27 | $7.17M derived: sum of 3 quarters · filed 2025-03-27 | $9.30M 10-K · filed 2025-03-27 |
| 2023-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $5.45M derived: sum of 2 quarters · filed 2024-11-06 | $7.58M 10-Q · filed 2024-11-06 | $9.24M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.09M 10-Q · filed 2024-08-08 | $6.76M derived: sum of 3 quarters · filed 2024-08-08 | $8.48M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.13M 10-Q · filed 2024-05-02 | $3.80M derived: sum of 2 quarters · filed 2024-05-02 | $5.51M derived: sum of 3 quarters · filed 2024-05-02 | $7.58M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $3.38M derived: sum of 2 quarters · filed 2024-03-05 | $5.45M derived: sum of 3 quarters · filed 2024-03-05 | $7.18M 10-K · filed 2024-03-05 |
| 2022-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.78M derived: sum of 2 quarters · filed 2023-11-07 | $5.51M 10-Q · filed 2023-11-07 | $6.95M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.80M 10-Q · filed 2023-08-03 | $5.23M derived: sum of 3 quarters · filed 2023-08-03 | $6.85M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.74M 10-Q · filed 2023-05-04 | $3.17M derived: sum of 2 quarters · filed 2023-05-04 | $4.78M derived: sum of 3 quarters · filed 2023-05-04 | $6.53M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $3.05M derived: sum of 2 quarters · filed 2023-03-02 | $4.79M derived: sum of 3 quarters · filed 2023-03-02 | $6.42M 10-K · filed 2023-03-02 |
| 2021-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $3.36M derived: sum of 2 quarters · filed 2022-11-09 | $4.99M 10-Q · filed 2022-11-09 | $6.42M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.38M 10-Q · filed 2022-08-04 | $4.81M derived: sum of 3 quarters · filed 2022-08-04 | $6.50M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $1.64M 10-Q · filed 2022-05-05 | $3.07M derived: sum of 2 quarters · filed 2022-05-05 | $4.75M derived: sum of 3 quarters · filed 2022-05-05 | $6.35M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $3.12M derived: sum of 2 quarters · filed 2022-03-03 | $4.72M derived: sum of 3 quarters · filed 2022-03-03 | $6.16M 10-K · filed 2022-03-03 |
| 2020-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.29M derived: sum of 2 quarters · filed 2021-11-04 | $4.73M 10-Q · filed 2021-11-04 | $4.71M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.04M 10-Q · filed 2021-08-05 | $3.02M derived: sum of 3 quarters · filed 2021-08-05 | $4.54M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $1.45M 10-Q · filed 2021-05-05 | $1.42M derived: sum of 2 quarters · filed 2021-05-05 | $2.94M derived: sum of 3 quarters · filed 2021-05-05 | $6.72M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $1.49M derived: sum of 2 quarters · filed 2021-03-04 | $5.28M derived: sum of 3 quarters · filed 2021-03-04 | $6.80M 10-K · filed 2021-03-04 |
| 2019-09-30 | $1.52M 10-Q · filed 2019-11-06 | $5.30M derived: sum of 2 quarters · filed 2019-11-06 | $6.82M 10-Q · filed 2020-11-05 | $7.62M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-06-30 | $3.78M 10-Q · filed 2019-08-05 | $5.31M 10-Q · filed 2020-08-07 | $6.10M derived: sum of 3 quarters · filed 2020-05-11 | $7.93M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-03-31 | $1.52M 10-Q · filed 2020-05-11 | $2.32M derived: sum of 2 quarters · filed 2020-05-11 | $4.15M derived: sum of 3 quarters · filed 2020-05-11 | $6.81M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $796.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $2.62M derived: sum of 2 quarters · filed 2020-03-05 | $5.29M derived: sum of 3 quarters · filed 2020-03-05 | $6.24M 10-K · filed 2020-03-05 |
| 2018-09-30 | $1.83M 10-Q · filed 2019-11-06 | $4.49M derived: sum of 2 quarters · filed 2019-11-06 | $5.45M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $2.66M 10-Q · filed 2019-08-05 | $3.62M 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $955.00K 10-Q · filed 2019-05-06 | |||
| 2017-12-31 | $15.12M 10-K · filed 2019-03-07 | |||
| 2013-12-31 | $903.00K 10-K · filed 2014-03-28 | |||
| 2012-12-31 | $982.29K 10-K · filed 2014-03-28 | |||
| 2011-12-31 | $633.45K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |